• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Lasting response after discontinuation of cemiplimab in a patient with locally advanced basal cell carcinoma.

作者信息

De Giorgi V, Trane L, Savarese I, Silvestri F, Venturi F, Zuccaro B, Scarfì F

机构信息

Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy.

Cancer Research Attilia Pofferi Foundation, Pistoia, Italy.

出版信息

Clin Exp Dermatol. 2021 Dec;46(8):1612-1614. doi: 10.1111/ced.14804. Epub 2021 Jul 29.

DOI:10.1111/ced.14804
PMID:34157152
Abstract
摘要

相似文献

1
Lasting response after discontinuation of cemiplimab in a patient with locally advanced basal cell carcinoma.局部晚期基底细胞癌患者停用西米普利单抗后的持久反应。
Clin Exp Dermatol. 2021 Dec;46(8):1612-1614. doi: 10.1111/ced.14804. Epub 2021 Jul 29.
2
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.西妥昔单抗治疗后局部晚期基底细胞癌：一项开放标签、多中心、单臂、2 期临床试验。
Lancet Oncol. 2021 Jun;22(6):848-857. doi: 10.1016/S1470-2045(21)00126-1. Epub 2021 May 14.
3
Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up.西米普利单抗用于刺猬抑制剂治疗后局部晚期基底细胞癌患者的2期开放标签、多中心、单臂研究：延长随访
J Am Acad Dermatol. 2024 Feb;90(2):414-418. doi: 10.1016/j.jaad.2023.08.111. Epub 2023 Oct 14.
4
Granular cell basal cell carcinoma: A rare variant.颗粒细胞基底细胞癌：一种罕见的变体。
Indian J Dermatol Venereol Leprol. 2015 Jul-Aug;81(4):420-2. doi: 10.4103/0378-6323.158652.
5
Use of PD-1 Inhibitors in the Treatment of Advanced Basal Cell Carcinoma.PD-1抑制剂在晚期基底细胞癌治疗中的应用。
Dermatol Surg. 2021 Nov 1;47(11):1511-1512. doi: 10.1097/DSS.0000000000003207.
6
CorrespondenceMetastatic basal cell carcinoma with neuroendocrine differentiation: complete response to cemiplimab.通信转移性基底细胞癌伴神经内分泌分化：对西米普利单抗完全缓解
Clin Exp Dermatol. 2024 Aug 22;49(9):1060-1062. doi: 10.1093/ced/llae099.
7
Anti-programmed cell death-1 therapy in nonmelanoma skin cancer.非黑色素瘤皮肤癌中的抗程序性细胞死亡-1疗法。
Br J Dermatol. 2017 Feb;176(2):498-502. doi: 10.1111/bjd.14664. Epub 2016 Oct 17.
8
Immune checkpoint inhibitors for advanced or metastatic basal cell carcinoma: how much evidence do we need?免疫检查点抑制剂治疗晚期或转移性基底细胞癌：我们需要多少证据？
Immunotherapy. 2021 Oct;13(15):1293-1304. doi: 10.2217/imt-2021-0089. Epub 2021 Aug 31.
9
Complete Remission of Basal Cell Carcinoma Following Treatment With Cemiplimab After 2 Years.使用西米普利单抗治疗2年后基底细胞癌完全缓解
JAMA Dermatol. 2021 Aug 1;157(8):1004-1006. doi: 10.1001/jamadermatol.2021.2206.
10
Long-term survival after anti-PD-1 discontinuation in advanced cutaneous squamous cell carcinoma (cSCC): a proof of concept of benefit of concomitant cemiplimab and radiotherapy.抗 PD-1 停药后晚期皮肤鳞状细胞癌 (cSCC) 的长期生存：同时使用西普利单抗和放疗获益的概念验证。
Cancer Immunol Immunother. 2024 May 7;73(7):118. doi: 10.1007/s00262-024-03700-x.

引用本文的文献

1
Prevalence of genetic alterations in basal cell carcinoma patients resistant to Hedgehog pathway inhibitors: a systematic review.对Hedgehog信号通路抑制剂耐药的基底细胞癌患者的基因改变患病率：一项系统评价
Ann Med. 2025 Dec;57(1):2516701. doi: 10.1080/07853890.2025.2516701. Epub 2025 Jun 16.
2
Cemiplimab in the treatment of metastatic basal cell carcinoma.西米普利单抗治疗转移性基底细胞癌。
Future Oncol. 2025 Jul;21(16):1999-2005. doi: 10.1080/14796694.2025.2511568. Epub 2025 May 27.
3
Cutaneous Toxicities of Advanced Treatment for Cutaneous Melanoma: A Prospective Study from a Single-Center Institution.
皮肤黑色素瘤晚期治疗的皮肤毒性：一项来自单中心机构的前瞻性研究。
Cancers (Basel). 2024 Oct 30;16(21):3679. doi: 10.3390/cancers16213679.
4
Basosquamous carcinoma: Comprehensive epidemiological, clinical, dermoscopic, and confocal features from a single center institution.基底鳞状细胞癌：来自单一中心机构的全面流行病学、临床、皮肤镜和共聚焦特征。
Skin Res Technol. 2024 Aug;30(8):e70012. doi: 10.1111/srt.70012.
5
Immunotherapy and Its Timing in Advanced Basal Cell Carcinoma Treatment.晚期基底细胞癌治疗中的免疫疗法及其时机选择
Dermatol Pract Concept. 2023 Oct 1;13(4):e2023252. doi: 10.5826/dpc.1304a252.
6
Complete response of a large basosquamous carcinoma following treatment with cemiplimab and vismodegib.西妥昔单抗联合维莫非尼治疗巨大基底细胞鳞癌完全缓解 1 例
BMJ Case Rep. 2023 Jul 14;16(7):e251273. doi: 10.1136/bcr-2022-251273.
7
Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response.非黑色素瘤皮肤癌患者中免疫治疗候选者的识别：反应潜在预测因素综述
J Clin Med. 2022 Jun 11;11(12):3364. doi: 10.3390/jcm11123364.
8
Treatment of Advanced Basal Cell Carcinoma with Hedgehog Pathway Inhibitors: A Multidisciplinary Expert Meeting.使用刺猬信号通路抑制剂治疗晚期基底细胞癌：多学科专家会议
Cancers (Basel). 2021 Nov 15;13(22):5706. doi: 10.3390/cancers13225706.